The US FDA’s plan to have sponsors submit up to 10 proposed suffixes for a biological product’s distinguishable nonproprietary name should reduce the review burden on agency staff while also helping to ensure that a company gets one of its preferred suffixes approved instead of having the agency assign one.
In a final guidance released Jan
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?